← All trials
NCT04746105
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 24, 2021
- Primary completion
- Oct 30, 2021
- Completion date
- Oct 30, 2021
- First posted
- Feb 9, 2021
- Last posted
- Nov 23, 2021
- Enrollment
- 46
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Taisho PharmaceuticalLead sponsor
- Taisho PharmaceuticalStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.